Categories: NewsPharmaceutical

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
  • Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress.

A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.

Staff

Recent Posts

IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1

Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to…

16 hours ago

Decisely Notifies Individuals of Data Security Incident

ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may…

1 day ago

Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records

NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians…

1 day ago

The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare

Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13,…

1 day ago

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture…

1 day ago

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

2 days ago